Abstract
The pricing of pharmaceutical products has recently been the subject of intense scrutiny, and much vilification, by both the public and Congress, especially when alternative therapies are not available and a specific segment of the population is denied access to the drug due to cost. ICI Pharmaceuticals, recognizing an ethical obligation to the needy public, established the Patient Assistance Program in 1978 to provide NOLVADEX® (tamoxifen citrate) to women with breast cancer, free-of-charge, when retail purchase of product would pose undue financial hardship
Get full access to this article
View all access options for this article.